Synonym
Vonafexor; EYP001; EYP-001; EYP 001;
IUPAC/Chemical Name
4-chloro-5-[4-(2,6-dichlorobenzene-1-
sulfonyl)piperazin-1-yl]-1-benzofuran-2-carboxylic acid
InChi Key
XLGQSYUNOIJBNR-UHFFFAOYSA-N
InChi Code
InChI=1S/C19H15Cl3N2O5S/c20-12-2-1-3-13(21)18(12)30(27,28)24-8-6-23(7-9-24)14-4-5-15-11(17(14)22)10-16(29-15)19(25)26/h1-5,10H,6-9H2,(H,25,26)
SMILES Code
O=C(C(O1)=CC2=C1C=CC(N3CCN(S(=O)(C4=C(Cl)C=CC=C4Cl)=O)CC3)=C2Cl)O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
489.75
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Ferrari FR, Giorgio C, Zappia A, Ballabeni V, Bertoni S, Barocelli E, Scalvini L, Galvani F, Mor M, Lodola A, Tognolini M. Pharmacological characterization of second generation FXR agonists as effective EphA2 antagonists: A successful application of target hopping approach. Biochem Pharmacol. 2023 Mar;209:115452. doi: 10.1016/j.bcp.2023.115452. Epub 2023 Feb 13. PMID: 36792038.
2: Ratziu V, Harrison SA, Loustaud-Ratti V, Bureau C, Lawitz E, Abdelmalek M, Alkhouri N, Francque S, Girma H, Darteil R, Couchoux H, Wolf M, Sanyal A, Vonderscher J, Scalfaro P. Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH. J Hepatol. 2023 Mar;78(3):479-492. doi: 10.1016/j.jhep.2022.10.023. Epub 2022 Nov 9. PMID: 36334688.
3: Erken R, Andre P, Roy E, Kootstra N, Barzic N, Girma H, Laveille C, Radreau- Pierini P, Darteil R, Vonderscher J, Scalfaro P, Tangkijvanich P, Flisiak R, Reesink H. Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study. J Viral Hepat. 2021 Dec;28(12):1690-1698. doi: 10.1111/jvh.13608. Epub 2021 Sep 29. PMID: 34467593; PMCID: PMC9293351.
